Sunday, July 22, 2007
Arq Gastroenterol. 2007
Coelho JC, Baretta GA, Okawa L.
Serviço de Cirurgia do Aparelho Digestivo, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR.
Dr. Júlio C. U. Coelho Rua Bento Viana, 1140 – apt.2202 80240-110 – Curitiba, PR E-mail: email@example.com
Headings: Abdomen. Infection. Cross infection. Anti-bacterial agents.
BACKGROUND: Intra-abdominal infections are common and are associated with elevated morbidity and mortality. The microorganisms that cause intra-abdominal infections are usually from the gastrointestinal flora, mainly E. coli and Bacteroides fragilis.
AIM: To present a review of the selection and use of antibiotics in intra-abdominal infections.
CONCLUSIONS: Appropriate use of antibiotics is essential to control infection and to reduce treatment failure. Antibiotics are initiated whenever intra-abdominal infection is suspected and the antimicrobial agents are selected based on the most common microorganisms involved. In addition, efficacy, cost, safety, and posologic regimen are considered for an appropriated selection. Antibiotic regimen is different whether the infection is acquired in the community or at hospital due to the more resistant flora in the latter.
Sunday, July 15, 2007
Braz J Infect Dis. 2007 Apr
Silva PS, Monteiro Neto H, Sejas LM.
Pediatric Intensive Care Unit, Department of Pediatrics, State Hospital of Diadema, Federal University of São Paulo, São Paulo, SP, Brazil.
Key-Words: Vancomycin, resistance, treatment
Enterococci are an uncommon cause of CNS infection. A 20 month-old boy, diagnosed with hydrocephalus with ventriculoperitoneal shunt and history of lengthy hospitalization and use of wide spectrum antibiotics, was admitted to the pediatric intensive care unit diagnosed with ventriculitis. On the 14th day of empirical antibiotic therapy (vancomycin and meropenem) the child presented fever while the CSF sample culture evidenced vancomycin-resistant Enterococcus faecium.
The patient received intravenous linezolid achieving cerebrospinal fluid sterilization.
Conclusion: Intravenous linezolid appears to be a safe and effective therapy for vancomycin-resistant enterococcus ventriculoperitoneal shunt infection.
A 20 month-old boy, with underlying diagnosis of neurodevelopmental delay and hydrocephalus with ventriculoperitoneal shunt (VPS) secondary to Pneumococcus meningitis at 6 months of life, presented a cardiorespiratory arrest on his arrival in hospital, and was then resuscitated over 23 minutes. The infant remained hospitalized for 10 days within the pediatric intensive care unit (PICU), diagnosed with aspirative pneumonia and cardiogenic shock, receiving oxacillin and ceftriaxone.
On the 18th day, the patient was readmitted to the PICU with a diagnosis of septic shock due to central venous catheter-related infection, being discharged from the PICU on the 7th day, having received vancomycin and cefepime for a total of 3 weeks. On the 39th day he was readmitted to the PICU diagnosed with ventriculitis. The cerebrospinal fluid (CSF) sample obtained by reservoir puncture revealed 71 cells/mm3 (72% neutrophils; glucose 13 mg/dL and protein 69 mg/dL). Cultures were negative. The patient received external ventricular drain associated with vancomycin and meropenem empirically for 4 weeks, undergoing a VPS on the 30th PICU day. On the 14th postoperative (PO) day, the patient developed perivalvular abscess, the CSF obtained from the shunt reservoir presented 74 cells/mm3 (79% neutrophils), upon which the patient was submitted to external ventricular shunt (EVS) whilst vancomycin and meropenem were resumed. On the 6th PO day after EVS, fluconazole was associated due to the presence of yeast in a routine CSF sample. Cultures for fungus were negative. On the 14th day of antibiotic therapy, the patient evolved with fever (39ºC), presenting the following laboratorial exams: white blood cells (WBC) 23,000/mm3, platelets 156,000/mm3, C-reactive protein 20 mg/dL, CSF with 15 cells (90% neutrophils), glucose 45 g/dL, protein 910 g/dL, Gram stain showed Gram-positive cocci in chains, and 2 serial CSF cultures yielded Enterococcus faecium resistant to vancomycin, ampicillin, streptomycin, ciprofloxacin, chloramphenicol and susceptible to gentamicin. The vancomycin minimum inhibitory concentration (MIC) of this isolate was > 32 µg/mL (using an E-test method with an inoculum density of 0.5 McFarland standard). Based on this information, he was switched to linezolid monotherapy, dosed at 10 mg/kg intravenously every 8 hours.
Following the 2nd day of linezolid, the patient became afebrile, and after the 3rd day had sterile CSF. Following 4-week treatment with linezolid, the patient had a new VPS in place (CSF: 1 cell/mm3, glucose 54 g/dL and protein 90 g/dL) and C-reactive protein of 1.78 mg/dL. Treatment continued for a further 2 weeks, during which time CSF samples remained sterile. Concentrations of linezolid in CSF were not recorded. The patient tolerated the 6-week treatment without showing evidence of bone marrow suppression. Fecal cultures obtained during treatment with linezolid were negative. The patient evolved requiring ventilation assistance due to neurologic compromise, and was cared for in an intermediate care unit.
The emergence of nosocomially acquired vancomycin-resistant enterococci has become a significant concern and a treatment challenge to physicians . Approximately 12% to 18% of enterococci in the United States exhibit vancomycin resistance .
Risk factors for vancomycin-resistant enterococcus (VRE) colonization in children include young age, use of invasive devices, antimicrobial drug administration, immunosuppression, low birth weight, and underlying malignancy . Such patients have commonly been treated with vancomycin or broad-spectrum antibiotics before VRE isolation . Two important factors predisposing patients to VRE infection are the percentage of hospital days receiving antimicrobial therapy of any type and the number of days receiving intravenous vancomycin . Our patient had received several weeks of broad-spectrum antibiotics before developing VRE meningitis; this prolonged use of antibiotics, associated with the long stay in hospital were likely contributory factors in both colonization and subsequent infection with VRE. However, treatment with lengthy courses of broad-spectrum antibiotics is often unavoidable in critically ill patients.
The National Nosocomial Infections Surveillance system of the Centers for Disease Control and Prevention reported vancomycin resistance in 28.5% of nosocomial enterococcal intensive care unit infections in 2003 . In a recent study, 14% of VRE-colonized patients progressed to infection within 15 days of a positive surveillance culture . A recent review noted that, although Enterococcus faecalis is responsible for 80% of enterococcal infections, E. faecium strains account for 98% of vancomycin-resistant cases .
There are no established guidelines for the treatment of central nervous system infection caused by VRE. Therapeutic options for vancomycin-resistant enterococci are limited because these organisms are usually resistant to multiple antimicrobial agents. Treatment often has to include investigational drugs or less tested new drugs. In our patient the therapy included intravenous linezolid. To the best of our knowledge, there has only been 1 previous case report of ventriculitis due to enterococcus in a child treated successfully with linezolid .
Linezolid, the first member of the oxazolidinones class of antibiotics licensed by the U.S. Food and Drug Administration (FDA), inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is approved for use in adults and children for serious infections caused by Enterococcus faecium or Enterococcus faecalis including vancomycin-resistant strains (VRE), Staphylococcus aureus including methicilllin-resistant strains (MRSA), coagulate-negative staphylococci and streptococci including penicillin-resistant Streptococcus pneumoniae . Linezolid is essentially bacteriostatic. In vitro time-kill experiments against multidrug-resistant (including vancomycin-resistant) enterococci, linezolid was not bactericidal but had greater bacteriostatic activity against these organisms .
CSF penetration of linezolid suggests utility in treatment of meningitis and intracranial prosthetic device infections. In individuals with noninflamed meninges, linezolid concentrations in CSF were 70% of plasma concentrations . In adults, reversible thrombocytopenia is the major hematologic consequence of linezolid use, generally occurring after > 2 weeks of treatment and thought to be due to transient bone marrow suppression. In children, thrombocytopenia is less common; however, a complete blood count should be monitored weekly while children are receiving linezolid . In adults, linezolid-induced neuropathy has been reported among patients receiving the drug for > 6 months.
Vancomycin and aminoglycosides with variable penetration of the blood-brain barrier and monitoring CSF levels is recommended. Intraventricular administration of antimicrobials with irregular penetration of blood-brain barrier makes theoretical sense but is controversial . Problems with intraventricular antibiotics include allergic reactions, drug-induced inflammation and toxic or inadequate concentrations . Even though our case presented gentamycin-susceptible enterococcus, the patient was successfully treated without needing intraventricular administration of drugs.
Optimal management of ventricular shunt infection requires removal of the shunt, placement of a temporary external ventricular drain (EVD), followed by reinternalization after CSF sterilization. A recent analysis strongly confirmed this as the most effective treatment method .
Length of time on antibiotic therapy in patients with ventriculoperitoneal shunt infection remains controversial. Studies employing linezolid for the treatment of VPS infections range from 3 to 12 weeks in length [4,8,20,21]. Despite receiving prolonged treatment, our patient presented no bone marrow compromise according to serial hemograms. However, peripheral neuropathic signs could not be assessed in this case because the patient presented severe neurologic compromise due to the underlying disease and comorbidity.
In conclusion, intravenous linezolid appears to be a safe and effective therapy for vancomycin-resistant enterococcus ventriculitis. Our success with linezolid in this instance is encouraging for the future role of this class of drugs for the treatment of shunt infections.ScieFLO Brazil
Pharmacokinetics and pharmacodynamics of antimicrobials
Clin Infect Dis. 2007 Jul
Antibiotics are some of our most commonly used drugs. Until recently, little has been known about how to optimize administration of these agents. Unfortunately, the rate of discovery of new antibiotics has been declining, coincident with the explosion in the number of multidrug-resistant organisms in both the community and hospital environments. This development makes the identification of optimal regimens that will result in good clinical and microbiological outcomes important, but it also makes clear the necessity of identifying regimens that will suppress the emergence of resistant organisms. Given that new agents for multidrug-resistant pathogens will take nearly a decade to become available to physicians, keeping organisms susceptible to drugs that are already available is even more critical. Pharmacodynamics allows identification of the drug exposure measure that is closely associated with the ability to kill organisms and, also, to suppress the emergence of resistant subpopulations of organisms. Use of Monte Carlo simulation allows identification of drug doses in the clinical arena to accomplish these ends. Such approaches should be applied to all old and new antibacterial agents.
Friday, July 06, 2007
Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial.
BMJ. 2007 Jun 29
Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ.
Nutrition and Dietetic Research Group, Faculty of Medicine, Imperial College, London W12 0HS.
OBJECTIVE: To determine the efficacy of a probiotic drink containing Lactobacillus for the prevention of any diarrhoea associated with antibiotic use and that caused by Clostridium difficile. DESIGN: Randomised double blind placebo controlled study.
PARTICIPANTS: 135 hospital patients (mean age 74) taking antibiotics. Exclusions included diarrhoea on admission, bowel pathology that could result in diarrhoea, antibiotic use in the previous four weeks, severe illness, immunosuppression, bowel surgery, artificial heart valves, and history of rheumatic heart disease or infective endocarditis.
INTERVENTION: Consumption of a 100 g (97 ml) drink containing Lactobacillus casei, L bulgaricus, and Streptococcus thermophilus twice a day during a course of antibiotics and for one week after the course finished. The placebo group received a longlife sterile milkshake.
MAIN OUTCOME MEASURES: Primary outcome: occurrence of antibiotic associated diarrhoea. Secondary outcome: presence of C difficile toxin and diarrhoea.
RESULTS: 7/57 (12%) of the probiotic group developed diarrhoea associated with antibiotic use compared with 19/56 (34%) in the placebo group (P=0.007). Logistic regression to control for other factors gave an odds ratio 0.25 (95% confidence interval 0.07 to 0.85) for use of the probiotic, with low albumin and sodium also increasing the risk of diarrhoea. The absolute risk reduction was 21.6% (6.6% to 36.6%), and the number needed to treat was 5 (3 to 15). No one in the probiotic group and 9/53 (17%) in the placebo group had diarrhoea caused by C difficile (P=0.001). The absolute risk reduction was 17% (7% to 27%), and the number needed to treat was 6 (4 to 14).
CONCLUSION: Consumption of a probiotic drink containing L casei, L bulgaricus, and S thermophilus can reduce the incidence of antibiotic associated diarrhoea and C difficile associated diarrhoea. This has the potential to decrease morbidity, healthcare costs, and mortality if used routinely in patients aged over 50. Trial registration National Research Register N0016106821.
PMID: 17604300 [PubMed - as supplied by publisher]